ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "T Cell"

  • Abstract Number: 2300 • ACR Convergence 2024

    Activation of Tissue-Resident T Cells in Sjögren’s Disease with Human Salivary Organoids

    Brandon Law1, Rahmatullah Rahmati2 and Andrew Luster3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts Eye & Ear, Boston, MA, 3Massachusetts General Hospital, Charlestown, MA

    Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, particularly the salivary glands. These focal lymphocytic infiltrates are…
  • Abstract Number: 0071 • ACR Convergence 2024

    Stage-Specific Roles of Interleukin-23/Interleukin-17 Axis and Type 1 Regulatory T Cells Dynamics in Axial Spondyloarthritis

    Jina Yeo1, Min-Gang Kim2, Hee Sung Kwon3, Mi Ryoung Seo1, Hyo-Jin Choi1, YunJae Jung4, Eun Young Lee5 and Han Joo Baek6, 1Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, 2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 4Department of Microbiology, College of Medicine, Gachon University, Incheon, Republic of Korea, 53Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 6Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Inchon, South Africa

    Background/Purpose: The interleukin (IL)-23/IL-17 pathway is central to axial spondyloarthritis (axSpA) pathogenesis, yet treatments targeting IL-23 show inconsistent effectiveness across spondyloarthritis subtypes. We hypothesized that…
  • Abstract Number: 0873 • ACR Convergence 2024

    Epigenetic Control of Pathogenic CD4 T Cell Polarization During Progression to Rheumatoid Arthritis (RA)

    Ziyuan He1, Pravina Venkatesan1, Adam Savage1, Marla Glass1, Lauren Okada2, Upaasana Krishnan2, Christy Bennett1, Nhung Tran2, Yudong He2, Samir Rachid Zaim1, Padmapriyadarshini Ravisankar2, Jessica Garber2, Palak Genge2, Kevin Lee2, Regina Mettey2, Cole Phalen2, Sugandhika Khosa2, Marie Feser3, Fan Zhang4, David Boyle5, Kristine Kuhn4, Kristen Demoruelle6, Cate Speake7, Jane Buckner8, Ananda Goldrath1, Thomas Bumol9, V. Michael Holers10, Peter Skene1, Gary Firestein11, Xiaojun Li1, Kevin Deane12, Troy Torgerson13 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2Allen Institute for Immunology, Seattle, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado, Aurora, CO, 5UCSD, La Jolla, CA, 6University of Colorado Anschutz Medical Campus, Golden, CO, 7Benaroya Research Institute at Virginia Mason, Seattle, 8Benaroya Research Institute, Seattle, WA, 9Allen Institute for Immunology, San Diego, CA, 10University of Colorado, Denver, CO, 11University of California, San Diego, San Diego, CA, 12University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 13Allen Institute for Immunology, Enumclaw, WA

    Background/Purpose: Multiple T cell subsets, including Th1, Th17 cells, and Tfh/Tph, contribute to rheumatoid arthritis (RA) pathology. Clinical trials have shown efficacy of T cell…
  • Abstract Number: 1659 • ACR Convergence 2024

    Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking

    Koen Venken1, Matthias Jarlborg1, Frederik Stevenaert2, Thomas Malfait3, Carolien Vlieghe1, Yann Abraham2, Teddy Manuello1, Tine Decruy1, Stijn Van Hee1, Hans Wils2, Pieter Peeters2, Philippe Carron4, Filip Van den Bosch3, Viggo Van Tendeloo2, Bart Lambrecht1, Ruth Wittoek5, Peggy Jacques6 and Dirk Elewaut7, 1VIB Center for Inflammation Research - Ghent University, Ghent, Belgium, 2Janssen Research and Development, Beerse, Belgium, 3Ghent University Hospital, Ghent, Belgium, 4UZ Gent, Gent, Belgium, 5Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, 6University Hospital of GHent, Gent, Belgium, 7Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

    Background/Purpose: Cigarette smoking has been associated with the production of anti-citrullinated protein antibodies (ACPA) and an increased risk of developing rheumatoid arthritis (RA) in individuals…
  • Abstract Number: 1838 • ACR Convergence 2024

    M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases

    Michelle Downing1, Ling Zhang1, Aditee Desphpande1, Hong Zhang1, Ohad Tarcic2, Mira toister-achituv2, Alec Gross3, Gang Chen3 and Chia Chi Sun1, 1EMD Serono Research and Development Institute, Inc., Billerica, MA, 2Inter-lab Ltd, Merck KGaA, Yavne, Israel, 3EMD Serono Reserch and Development Institute, Inc, Billerica, MA

    Background/Purpose: Overactive adaptive immune responses contribute to many autoimmune diseases such as systemic lupus erythematosus (SLE). Chronically activated autoreactive T-effector cells play a pivotal role…
  • Abstract Number: 1857 • ACR Convergence 2024

    Thymic Mimetic Cells in Humans, Mice and Fish Are Evolutionarily Ancient with Species-specific Adaptations

    Brooke Huisman1, Daniel Michelson1, Sara Rubin1, Katherine Kohlsaat2, Wilson Gomarga2, Yuan Fang1, Ji Myung Lee2, Pedro del Nido2, Meena Nathan2, Christophe Benoist1, Leonard Zon2 and Diane Mathis1, 1Harvard Medical School, Boston, MA, 2Boston Children's Hospital, Boston, MA

    Background/Purpose: Thymic mimetic cells are molecular hybrids between medullary thymic epithelial cells (mTECs) and diverse peripheral cell types. They are involved in eliminating autoreactive T…
  • Abstract Number: 2386 • ACR Convergence 2024

    Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity

    Alexandra Reese1, Chandana Keshavamurthy2, Sneha Centala1, Samantha Ahrens1, Shivani Shah2, Douglas Reeves2, William Davis3, Robert Quinet4, Jerald Zakem1, Qingli Wu1, Kimmy Tran1, Teresa Leeth5, Daniyal Nadeem6, Sarwat Umer7, Samina Hayat5 and Xin Zhang1, 1Ochsner Health, New Orleans, LA, 2Ochsner Clinic Foundation, New Orleans, 3Ochsner Health System, New Orleans, LA, 4Ochsner Health, River Ridge, LA, 5Louisiana State University Shreveport, Shreveport, LA, 6LSU Shreveport, Shreveport, 7LSU HEALTH SHREVEPORT, SHREVEPORT, LA

    Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by autoantibodies and disruption of multiple organs due to immunomodulatory dysfunction. Obesity is a…
  • Abstract Number: 0073 • ACR Convergence 2024

    Self or Bacteria-reactive Th17 Expand from Conventional and Regulatory T Cells in Parabacteroides Goldsteinii Gnotobiotic Arthritic SKG Mice, in Context of Interferon-driven Synovial Inflammatory Macrophages and Reduced Bacterial Immune Regulation

    Benjamin Cai1, Zewen Kelvin Tuong2, Mark Morrison1, Anne-Sophie Bergot1 and Ranjeny Thomas3, 1Frazer Institute, University of Queensland, Brisbane, Australia, 2Child Health Research Centre, University of Queensland, South Brisbane, Queensland, Australia, 3University of Queensland, Brisbane, Australia

    Background/Purpose: In ankylosing spondylitis, spondyloarthritis (SpA) is often associated with gut inflammation. The strong genetic association with HLA-B27 and expanded CD8 TCR public clonotypes implicate…
  • Abstract Number: 0874 • ACR Convergence 2024

    Defining a Protective Role for Mucosal-associated Invariant T (MAIT) Cells in Spontaneous Cutaneous Lupus Erythematosus

    Grace Crossland1, Lindsay Mendyka2, Michael Constantinides3 and Sladjana Skopelja-Gardner1, 1Dartmouth Geisel School of Medicine, Lebanon, NH, 2Dartmouth Hitchcock Memorial Hospital, Lyme, NH, 3Scripps Research Institute, San Diego, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of death in young females, and 70-85% of patients experience skin disease (cutaneous LE, CLE). The…
  • Abstract Number: 1661 • ACR Convergence 2024

    Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation

    Melissa Romoff1, Daniel Ramirez2, Edward Dicarlo3, Susan Goodman4, Alexander Rudenska5, Laura Donlin1 and Melanie Smith1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Cartago, Costa Rica, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, New York 10025, NY, 5Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: In the rheumatoid arthritis (RA) joint, resident synovial fibroblasts (FLS) interact with infiltrating leukocytes. We previously identified a population of sublining FLS responsive to…
  • Abstract Number: 1840 • ACR Convergence 2024

    Synovial Resident Memory T Cell Formation During Inflammation Requires Cell Contact with Fibroblast-Like Synoviocytes

    Yusuke Miyashita1, Yang Yang1, Madison Mangin1, Maryrose Hahn2, Kevin Wei3, Peter Nigrovic4 and Margaret Chang1, 1Boston Children's Hospital, Boston, MA, 2Boston Children's Hospital, Georgetown, MA, 3Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 4Boston Children's Hospital, Brookline, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by recurrent inflammation in the same joints, a feature termed joint-specific memory. We previously demonstrated…
  • Abstract Number: 1858 • ACR Convergence 2024

    Co-modification of Citrullinated Proteins with Malondialdehyde-Acetaldehyde Leads to Amplified T Cell Responses and Increased Disease-specific Autoantibody Concentrations

    Breanna Butler1, Wenxian Zhou2, Michael Duryee1, Nozima Aripova1, Engle Sharp1, Carlos Hunter1, Bridget Kramer1, Harlan Sayles1, James O'Dell1, Geoffrey Thiele1, Bryant England1, Joshua Baker3, Andreas Reimold4, Gail Kerr5 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE, 3University of Pennsylvania, Philadelphia, PA, 4Dallas VA Medical Center, Dallas, TX, 5Washington DC VAMC/Georgetown and Howard Universities, Washington, DC

    Background/Purpose: Anti-citrullinated protein antibody (ACPA) is highly specific to rheumatoid arthritis (RA). Beyond citrullination, other post-translational protein modifications including malondialdehyde-acetaldehyde (MAA) are targeted by T…
  • Abstract Number: 2427 • ACR Convergence 2024

    Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Induces Multicompartmental B Cell Depletion in Peripheral Blood, Bone Marrow and Lymph Nodes of Systemic Lupus Erythematosus

    Ioanna Minopoulou1, Olaf Penack2, Fredrik Albach1, Artur Wilhelm3, Arnd Kleyer4, Dominic Borie5, Vincent Casteleyn1, Robert Biesen1, Philipp Enghard6, Thomas Dörner7, Norman Drzeniek8, Jan Zernicke1, Tobias Alexander3, Kamran Movassaghi2, Marie Luise Hütter-Krönke9, Eva Schrezenmeier6, Adrian Schreiber10, udo schneider1, Lars Bullinger11, Gerhard Krönke12 and David Simon13, 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, 2Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, 4Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/ Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, 5Kyverna Therapeutics, Inc., Emeryville, CA, 6Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany/ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, 7Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, 8Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany/ Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin-Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany/Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Immunology, Berlin, Germany, Berlin, Germany, 9Department of Hematology, Oncology and Cancer Immunology, Charité University Medicine Berlin, Campus Steglitz, Berlin, Germany, Berlin, Germany, 10Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany, Berlin, Germany, 11Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany/ Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, Berlin, Germany, 12Rheumatology, Charité, Berlin, Germany, 13Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany

    Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cells have emerged as a promising therapeutic option for treatment-refractory patients with B cell-mediated diseases such as systemic…
  • Abstract Number: 0082 • ACR Convergence 2023

    A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model

    Adam Cartwright1, Foram Desai2, Sophia Nguyen2, Alexandra Trouilloud2, Elisa Liardo1, Daric Wible2, Ilaria Lamberto2, Bradley Demarco2, Chris King2, Debora Bonenfant1, Sharon Townson2, Owen Wallace2, Filip Janku2, Laura McAllister1, Alison Paterson2 and Marisa Peluso2, 1Monte Rosa Therapeutics, Basel, Switzerland, 2Monte Rosa Therapeutics, Boston, MA

    Background/Purpose: VAV1 is a member of the VAV family of guanine nucleotide exchange factors (GEFs) and plays a critical role in mediating T- and B-cell…
  • Abstract Number: 0455 • ACR Convergence 2023

    Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial

    Kenneth Luu, Martin Dahl, Eric Hare, Cailin Sibley, Paul Lizzul and Bruce Randazzo, AnaptysBio, San Diego, CA

    Background/Purpose: PD-1 pathway mutations increase human susceptibility to multiple autoimmune diseases, and insufficient PD-1 signaling can lead to dysregulated T cell responses. By targeting natural…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology